EligibleTrials

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Recruiting · NCT06848348 · Interventional (participants receive a specific treatment) · Lead sponsor: Dogwood Therapeutics Inc.

View the official record on ClinicalTrials.gov →
Colorectal cancerBreast cancer

Interventions studied

HalneuronHalneuron (Open Label Extension)Placebo

What this trial is about

A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

25 locations listed across 14 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.